Oct 25,2023

Glooko Appoints Enrique Conterno, former Eli Lilly & Company Senior Executive, to Board of Directors

Glooko announced the appointment of Enrique Conterno to its Board of Directors. Mr. Conterno is a well-known executive in the pharmaceutical industry with deep expertise in the diabetes field. He joins the board of Glooko having served most recently as the Chief Executive Officer and a member of the Board at FibroGen, Inc. Before FibroGen, Mr. Conterno was Senior Vice President for Eli Lilly and Company, serving as President of Lilly USA from January 2017, and President of Lilly Diabetes from 2009, until his retirement from Lilly in December 2019.

View Analyst & Ambassador Comments
Go to original news
Oct 23,2023 TOP STORY

Insulet Announces FDA 510(k) Clearance of the Omnipod® 5 App for iPhone

Insulet announced it has received FDA 510(k) clearance for the Omnipod 5 App for iPhone, making the Company eligible to offer a tubeless automated insulin delivery (AID) system with full control from a compatible Android and iOS smartphone. Since its full commercial launch in August 2022 in the United States, the Omnipod 5 Automated Insulin Delivery System has included the option for smartphone control for customers using compatible Android devices. With today’s announcement, the Omnipod 5 Pod will soon be controllable from a compatible iPhone. The Omnipod 5 App for iPhone will launch first with the Dexcom G6 Continuous Glucose Monitoring System integration, with a full market release in 2024.

REGULATORY FDA

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Oct 23,2023

Smart Insulin Pens Market Size Projected to Attain $191.26 Million by 2032

The global smart insulin pens market size is anticipated to grow from USD 67.91 million to USD 191.26 billion in 2032, according to the research publisher. The market will experience rapid growth due to the increasing incidence of diabetes during the forecast period. The high investment in research and development of high-end and next-generation smart insulin pens will lead to a substantial growth rate in the market.

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Oct 24,2023 TOP STORY

Signos Announces Series B Funding Round of $20 Million

Signos, a metabolic health platform that utilizes a unique AI-engine with a continuous glucose monitor (CGM) to offer real-time data and recommendations for healthy weight management, has announced a successful $20 million Series B funding round. The round was led by Cheyenne Ventures and GV (Google Ventures), with additional investments from Dexcom Ventures and Samsung. It will enable Signos to expand its team, extend its platform and conduct further research on metabolic health. The Signos app allows users to log their food intake and exercise levels, enabling the AI platform to learn how an individual’s metabolism responds to various foods and fitness patterns. This information then provides personalized, data-driven recommendations based on an individual’s unique metabolic profile.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Oct 19,2023

Pioneering Welsh company secures prestigious award for revolutionary diabetes device

Afon Technology has been awarded a prestigious Wales STEM Award for the creation of the world’s first non-invasive wearable blood glucose sensor. Afon Technology’s non-invasive continuous blood glucose monitoring sensor is worn on the inside of the wrist with or without a watch, and it feeds back to the user’s chosen smart device to display blood glucose data. Unlike the current continuous glucose monitoring devices, it will measure blood glucose levels in real-time without the need to penetrate the skin at all.

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 19,2023 TOP STORY

GE HealthCare and Novo Nordisk to Collaborate to Advance Novel Non-Invasive Treatment for Type 2 Diabetes and Obesity with Ultrasound

GE HealthCare announced a collaboration with Novo Nordisk to further advance the clinical and product development of peripheral focused ultrasound (PFUS). This is a novel technology that has potential to specifically regulate metabolic function in the body using ultrasound that may support the treatment of chronic diseases such as type 2 diabetes and obesity. PFUS is a non-invasive type of bioelectronic medicine that uses ultrasound to activate the nervous system to stimulate a response that may be able to treat disease. Pre-clinical proof of concept and initial early-stage clinical research suggests that it may impact glucose metabolism in people with diabetes via personalized ultrasound stimulation of nerve pathways. If validated with further clinical evidence, PFUS could represent a non-pharmacologic approach to normalize blood glucose levels in people with type 2 diabetes. As part of the collaboration, GE HealthCare and Novo Nordisk will contribute their respective expertise in ultrasound medical technology and metabolic disease treatment and management as both parties work together to develop a PFUS solution.

COLLABORATION PARTNERSHIP

#r&d

View Analyst & Ambassador Comments
Go to original news
Oct 18,2023 TOP STORY

Abbott Reports FreeStyle Libre Sales Growth of 30% in Q3 2023 Financials

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2023. In Diabetes Care, FreeStyle Libre sales were $1.4 billion, which represents sales growth of 30.5 percent on a reported basis and 28.5 percent on an organic basis. Additionally, in September 2023, Abbott acquired Bigfoot Biomedical, a leader in developing insulin management systems, furthering Abbott's efforts to develop connected solutions for making diabetes management even more personal and precise. Abbott also published an analysis showing a complementary relationship between the company's FreeStyle Libre® continuous glucose monitoring system and GLP-1 medications. The analysis also showed that a growing number of people are using these tools together to support behavior change to optimize the treatment of diabetes and improve overall health.

View Analyst & Ambassador Comments
Go to original news
Oct 18,2023 TOP STORY

Noom Announces Navitus Health Solutions as Latest Noom for Work Partner

Noom announced that its enterprise unit, Noom for Work, has entered into a partnership with Navitus Health Solutions, LLC, a unique pass-through pharmacy benefit manager (PBM), to help its clients and members gain better physical and mental health outcomes through Noom Weight, Noom Diabetes Prevention Program, and Noom Mood. These programs are also available for clients of EpiphanyRx, Navitus’ in-house solution for emerging market employers. As employers and payers are continually looking for opportunities to drive efficiencies, uncover cost savings, and bring cutting-edge programs to their clients and members, Noom for Work provides an all-in-one platform that meets these needs.

COLLABORATION PARTNERSHIP

#institution

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Oct 16,2023 TOP STORY

Better Therapeutics Announces Launch of AspyreRxTM to Treat Adults with Type 2 Diabetes

Better Therapeutics announced the commercial launch of AspyreRx, the first cognitive behavioral therapy (CBT) app to receive U.S Food and Drug Administration (FDA) authorization as a Class II device to treat adults with type 2 diabetes (T2D). Licensed healthcare providers are now able to prescribe AspyreRx via EMR and PhilRx will determine the insurance coverage. The app is available for download on the Apple App and Google Play Stores.

PRODUCT

#dtx

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES